NCT03093116 2026-05-27TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT06993844 2026-05-06Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsEnsem TherapeuticsPhase 1/2 Recruiting233 enrolled